Psychedelic therapy uses substances like MDMA and psilocybin in controlled clinical settings to treat PTSD, depression, and end-of-life anxiety, undergoing FDA breakthrough therapy designation trials 2017-2023.
Clinical Renaissance
After decades of prohibition, psychedelic research resurged in the 2010s through organizations like MAPS (Multidisciplinary Association for Psychedelic Studies). Phase 3 trials for MDMA-assisted therapy for PTSD (2018-2023) showed 67% no longer meeting PTSD criteria, leading to FDA breakthrough therapy status.
Johns Hopkins psilocybin trials (2016-2022) demonstrated efficacy for treatment-resistant depression and cancer-related anxiety, with effects lasting months after a single session.
Substances & Applications
MDMA (Ecstasy)
- PTSD treatment (2018-2023 Phase 3 trials)
- Enhances therapeutic rapport, reduces fear response
- Expected FDA approval 2024
Psilocybin (Magic Mushrooms)
- Treatment-resistant depression
- End-of-life anxiety (terminal cancer patients)
- FDA breakthrough therapy status 2019
Ketamine
- Already legal for off-label depression use (2019+)
- Rapid-acting antidepressant effects
- Clinic proliferation 2019-2023
Mainstream Acceptance (2019-2023)
Media coverage exploded 2019-2021:
- Michael Pollan’s How to Change Your Mind (2018 book, 2022 Netflix series)
- 60 Minutes MDMA therapy feature (2021)
- Oregon legalizing psilocybin therapy (2020, services 2023)
- VC funding psychedelic biotech startups
Social Media Trends
Instagram/TikTok psychedelic content 2020-2023:
- Trip integration coaches
- Microdosing productivity claims (controversial)
- Spiritual vs. medical framing debates
- Indigenous medicine appropriation concerns
Criticism
- Medicalization erasing Indigenous ceremonial contexts
- Venture capital commodifying sacred medicines
- Overhyped as “cure” for mental illness
- Safety concerns (psychosis risk, cardiac issues)
- Psychedelic exceptionalism ignoring existing effective treatments
Therapeutic Protocol
MDMA/psilocybin therapy typically involves:
- Preparation sessions (therapist rapport, intention setting)
- Dosing session (6-8 hours, two therapists, music, eyeshades)
- Integration sessions (processing insights, behavioral change)
Influential Figures
- Rick Doblin (MAPS founder, MDMA trials)
- Roland Griffiths (Johns Hopkins psilocybin research, d. 2023)
- Robin Carhart-Harris (Imperial College, psilocybin depression trials)
- Michael Pollan (science journalism popularization)
Related hashtags: #MDMATherapy #Psilocybin #KetamineTherapy #MentalHealthRevolution #PsychedelicScience